1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Achiko AG
  6. News
  7. Summary
    ACHI   CH0522213468

ACHIKO AG

(ACHI)
  Report
Delayed Swiss Exchange  -  11:36 2022-06-29 am EDT
0.0400 CHF   +33.33%
06/28Achiko AG – Suspension of Trading
AQ
06/28Achiko Shares Suspended From Trading On SIX Exchange
MT
06/27Swiss Diagnostic Testing Group Achiko's FY21 Loss Shrinks on Lower Expenses
MT
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Achiko AG Reports Key Unaudited Financial Results for the Year Ended 31 December 2021

05/19/2022 | 12:49am EDT

Achiko AG / Key word(s): Annual Results
Achiko AG Reports Key Unaudited Financial Results for the Year Ended 31 December 2021

19-May-2022 / 06:45 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Achiko AG Reports Key Unaudited Financial Results for the Year Ended 31 December 2021

- Full year unaudited adjusted EBITDA of USD$5,272,179 (2020: USD$8,728,709) following 6 months unaudited of USD$3,915,136 to 30 June 2021 and closing Shareholders Equity of USD$4,297,969 (2020: $4,052,073).

- Restructuring of the European operations in mid-2021 resulted in lower operating costs in the secondhalf of the year and a smaller loss with a stronger execution record in the last 6 months.

- Audited accounts at the end of the month and AGM in June 2022.

Zurich, 19 May 2022: Ad hoc announcement pursuant to Art. 53 LR ? Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (?Achiko?, the ?Company?) is pleased to report ahead of audited accounts to be presented later this month, the key unaudited financial results for the Company for the period ending 31 December 2021.

After reporting an adjusted EBITDA (excluding stock-based compensation) of USD$3,915,136 in the 6 months period to 30 June 2021, adjusted EBITDA for the full year was USD$5,272,179 (2020: $8,728,709). Revenue for the full year was USD$60,014 (2020: $2,805,708) representing the transition period between one business and another and closing Shareholder?s Equity at 31 December 2021 was USD$4,297,969 (2020: $4,052,073).

These numbers may be updated when the Company completes work around stock-based compensation and the audit. The Company expects share-based compensation to fall significantly from the first half of the year as any additional grants to secure replacement or alternative personnel as part of the Company's restructuring were significantly lower later in the year than in prior periods.

?To better allocate shareholder capital to measuring the performance of our low cost AptameX? Covid-19 rapid test and have it registered and ready for sale, the Company restructured its operating footprint in Europe in the middle of 2021?, stated Steven Goh, CEO of Achiko AG.

?Whilst the Company faced a challenging restructure in the second half of the year, the recent string of post balance sheet execution milestones vindicates the investment?, added Goh. ?These include being able to report a financing in August and September 2021, solid product performance results in January 2022, a strong marketing and sales deal in April with Nahdlatul Ulama and Indopharma, and finally obtaining a CE Mark a few days ago. We are confident that the leaner organization is able to execute more decisively going forward.?

The Company expects to publish audited accounts and an annual report before month?s end and hold an Annual General Meeting on 27 June 2022.

ABOUT ACHIKO AG
Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that puts people first. The company?s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021, in May 2022 AptameX received the CE Mark in the European Union.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameXTM and companion health apps via its digital mobile health technology division, Teman SehatTM. The AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Media contacts:

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


Additional features:


File: Achiko AG Reports Key Unaudited Financial Results for the Year Ended 31 December 2021

End of ad hoc announcement
Language: English
Company: Achiko AG
Tessinerplatz 7
8002 Zurich
Switzerland
E-mail: ir@achiko.com
Internet: https://www.achiko.com/
ISIN: CH0522213468
Valor: 48788430
Listed: SIX Swiss Exchange
EQS News ID: 1356193

 
End of Announcement EQS News Service

1356193  19-May-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1356193&application_name=news&site_id=zonebourse_sftp

© EQS 2022
All news about ACHIKO AG
06/28Achiko AG – Suspension of Trading
AQ
06/28Achiko Shares Suspended From Trading On SIX Exchange
MT
06/27Swiss Diagnostic Testing Group Achiko's FY21 Loss Shrinks on Lower Expenses
MT
06/26Achiko AG Announces Annual Results for the Year Ended December 31, 2021
AQ
06/26Achiko AG Announces Annual Results for the Year Ended 31 December 2021
EQ
06/21GLOBAL MARKETS LIVE : Hermes, Tesla, Apple, Intel, Visa...
06/21Achiko AG Reports Earnings Results for the Full Year Ended December 31, 2021
CI
06/20Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to ..
AQ
06/20Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to ..
EQ
06/10Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to ..
AQ
More news
Analyst Recommendations on ACHIKO AG
More recommendations
Financials (USD)
Sales 2020 2,81 M - -
Net income 2020 -14,1 M - -
Net Debt 2020 1,57 M - -
P/E ratio 2020 -2,61x
Yield 2020 -
Capitalization 5,56 M 5,56 M -
EV / Sales 2019 -
EV / Sales 2020 14,0x
Nbr of Employees 29
Free-Float 65,8%
Chart ACHIKO AG
Duration : Period :
Achiko AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACHIKO AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Steven Goh Chief Executive Officer & Director
Morris S. Berrie President
Adam O’Keeffe Chief Financial Officer
Yao Bian Wu Chairman
Ann Chow Head-Investor Relations
Sector and Competitors
1st jan.Capi. (M$)
ACHIKO AG-82.76%6
INTUIT INC.-39.94%108 964
FIDELITY NATIONAL INFORMATION SERVICES, INC.-13.63%57 311
ADYEN N.V.-38.70%46 189
WORLDLINE-22.89%11 172
HITHINK ROYALFLUSH INFORMATION NETWORK CO., LTD.-34.35%7 854